Erik de Blois

Erik de Blois (1981, Zeist) started his MLO training at Zadkine Rotterdam and graduated in 2001 in biotechnology. He then studied part-time at HLO at the HvU Utrecht and graduated in 2005. In the following year he continued his part-time study in pharmaceutical sciences at the University of Utrecht in the direction of "Drug innovation". He graduated in 2009, after which he started his PhD program part-time at Erasmus MC. In 2014 he successfully defended his thesis: Radiochemical Aspect of receptor Scintigraphy: labeling with radiometals, optimization and radiochemical purity and obtained his doctorate. In the meantime, he started in 2002 as a research analyst in the radiochemistry group at the Nuclear Medicine department at Erasmus MC. After obtaining his Master's degree, his position changed to Clinical Radiochemist and is responsible for the clinical implementation of new non-registered radiopharmaceuticals. Since 2021 he is also Head of Quality Control and responsible for the release of radiopharmaceuticals made in-house. Within his position he contributed to the implementation of various (therapeutic) radiopharmaceuticals, including the first registered drug Lu-177 labeled DOTA-TATE (Lutathera®). In 2018 he became board member (treasurer) of the Dutch Society of clinical radiochemistry (NKRV) and in 2022 also board member of the Dutch Society of nuclear medicine (NVNG).